HOME >> BIOLOGY >> NEWS
Vertex Pharmaceuticals Researchers Report Three-Dimensional Structure Of Hepatitis C Helicase Enzyme; Report In Structure

Cambridge, MA, January 15, 1998 -- Researchers from Vertex Pharmaceuticals Incorporated have solved the three-dimensional atomic structure of the hepatitis C virus NS3 helicase, an enzyme that plays a key role in viral replication. The achievement is described in a paper, "Hepatitis C Virus NS3 RNA Helicase Domain with a Bound Oligonucleotide: The Crystal Structure Provides Insights into the Mode of Unwinding," published in the January 15, 1998 issue of the journal Structure. The publication follows the presentation of the helicase structure at the Second International Conference on Therapies for Viral Hepatitis in Kona, Hawaii, in December 1997. Vertex is using the structural information to design hepatitis C helicase inhibitors as new antiviral drugs to treat hepatitis C virus (HCV) infection.

"This paper presents for the first time detailed information on the critical interaction between the hepatitis C helicase and viral RNA," said Dr. Joseph L. Kim, Vertex crystallographer and an author of the Structure paper. "The nucleic acid binding site of the helicase enzyme, as well as the previously described nucleoside triphosphate (NTP) binding site, are attractive targets for disrupting this interaction. These two targets, which comprise the active sites of the helicase enzyme, are a focus of our ongoing drug design efforts."

Helicases are enzymes distinguished by their ability to unwind regions of double-stranded RNA or DNA, in preparation for replication or transcription of genetic information. In the case of hepatitis C, the NS3 helicase functions to unwind double-stranded viral RNA complexes. The resulting RNA strands then serve as templates for the synthesis of more RNA or for translation into protein. Alternately, the new RNA may be packaged into new virus particles, which are released from cells to propagate infection.

Vertex scientists determined the three-dimensional structure of h
'"/>

Contact: Michael Partridge
partridge@vpharm.com
(617) 577-6108
Vertex Pharmaceuticals
15-Jan-1998


Page: 1 2 3 4

Related biology news :

1. Research Findings Suggest Potent, Broad-Spectrum Antiviral Activity For Vertexs Investigational IMPDH Inhibitor VX-497
2. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
3. Vertex Researchers Report Three-Dimensional Atomic Structure Of JNK3 Enzyme; Report In Structure
4. Vertex Pharmaceuticals/Yale Research Team Uses Gene Knockout Mice To Establish Role Of Caspase-9 In Neuronal Cell Death Pathway
5. Warren Pharmaceuticals publishes results of preclinical evaluation
6. Cyclis Pharmaceuticals reports studies defining new mechanism for potential cancer therapies
7. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
8. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
9. Idun Pharmaceuticals Identifies Cell Type And Molecular Pathway Involved In TransplantationRelated Liver Damage
10. Cubist Pharmaceuticals Describes New VITA™ Technology For Enabling Genomics For Drug Discovery
11. Scientists At The Scripps Research Institute And R.W. Johnson Pharmaceuticals Develop New Antibacterial Agents

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology:
Cached News: